EXEL is trading at 5.2% up now at $56.78 in pre-market, a strong move versus its recent tight trading range. So far, there are no fresh earnings, FDA, M&A, or major analyst headlines since its Q1 2026 results and guidance update, suggesting the jump may be driven by opportunistic buying in a firm with solid fundamentals and ongoing oncology pipeline momentum rather than a specific new announcement.